异环磷酰胺（IFO）是新一代恶唑酰胺氮芥类抗肿瘤药，为环磷酸胺（CTX）的同分异构体，多种实验肿瘤试验显示了IFO比CTX具有较高的治疗活性及较低的毒性。我科用IFO联合方案对22例难治性非何杰金淋巴瘤（NHL）患者进行了疗效及毒性观察，现总结如下。1材料和方法临床资料本组22 Ifosfamide (IFO) is a new generation of oxazolamide nitrogen mustard anti-tumor drugs, isomers of cyclophosphamide (CTX), a variety of experimental tumor tests show that IFO has higher therapeutic activity than CTX And lower toxicity. In our department, 22 patients with refractory non-Hodgkin’s lymphoma (NHL) were evaluated for efficacy and toxicity using the IFO combination protocol and are summarized below. 1 Materials and Methods Clinical Data Group 22